Evidence map›Paper›PMID 36004907›Full record

ArticleBioengineering (Basel, Switzerland)2022

Isoliquiritigenin Nanoemulsion Preparation by Combined Sonication and Phase-Inversion Composition Method: In Vitro Anticancer Activities.

Jianman Wang, Hongjin Chen, Tao Guo, Ping Yue, Tianbao Qian, Xiangyu Zeng, Yali Luo, Jiangmin Li, Lijing Teng, Qingyu Liu and 3 more

Abstract read
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jianman WangKey Laboratory of Infectious Immune and Antibody Engineering of Guizhou Province, Engineering Research Center of Cellular Immunotherapy of Guizhou Province, School of Basic Medical Sciences/School of Biology and Engineering, Guizhou Medical University, Guiyang 550025, China.
Hongjin ChenDepartment of Cardiovascular Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang 550009, China.
Tao GuoKey Laboratory of Infectious Immune and Antibody Engineering of Guizhou Province, Engineering Research Center of Cellular Immunotherapy of Guizhou Province, School of Basic Medical Sciences/School of Biology and Engineering, Guizhou Medical University, Guiyang 550025, China.
Ping YueKey Laboratory of Infectious Immune and Antibody Engineering of Guizhou Province, Engineering Research Center of Cellular Immunotherapy of Guizhou Province, School of Basic Medical Sciences/School of Biology and Engineering, Guizhou Medical University, Guiyang 550025, China.
Tianbao QianKey Laboratory of Infectious Immune and Antibody Engineering of Guizhou Province, Engineering Research Center of Cellular Immunotherapy of Guizhou Province, School of Basic Medical Sciences/School of Biology and Engineering, Guizhou Medical University, Guiyang 550025, China.ORCID 0000-0002-2362-0400
Xiangyu ZengKey Laboratory of Infectious Immune and Antibody Engineering of Guizhou Province, Engineering Research Center of Cellular Immunotherapy of Guizhou Province, School of Basic Medical Sciences/School of Biology and Engineering, Guizhou Medical University, Guiyang 550025, China.
Yali LuoKey Laboratory of Infectious Immune and Antibody Engineering of Guizhou Province, Engineering Research Center of Cellular Immunotherapy of Guizhou Province, School of Basic Medical Sciences/School of Biology and Engineering, Guizhou Medical University, Guiyang 550025, China.
Jiangmin LiKey Laboratory of Infectious Immune and Antibody Engineering of Guizhou Province, Engineering Research Center of Cellular Immunotherapy of Guizhou Province, School of Basic Medical Sciences/School of Biology and Engineering, Guizhou Medical University, Guiyang 550025, China.
Lijing TengKey Laboratory of Infectious Immune and Antibody Engineering of Guizhou Province, Engineering Research Center of Cellular Immunotherapy of Guizhou Province, School of Basic Medical Sciences/School of Biology and Engineering, Guizhou Medical University, Guiyang 550025, China.
Qingyu LiuKey Laboratory of Infectious Immune and Antibody Engineering of Guizhou Province, Engineering Research Center of Cellular Immunotherapy of Guizhou Province, School of Basic Medical Sciences/School of Biology and Engineering, Guizhou Medical University, Guiyang 550025, China.ORCID 0000-0001-6279-5927
Liang HongKey Laboratory of Infectious Immune and Antibody Engineering of Guizhou Province, Engineering Research Center of Cellular Immunotherapy of Guizhou Province, School of Basic Medical Sciences/School of Biology and Engineering, Guizhou Medical University, Guiyang 550025, China.ORCID 0000-0002-1614-440X
Zijiang YuKey Laboratory of Infectious Immune and Antibody Engineering of Guizhou Province, Engineering Research Center of Cellular Immunotherapy of Guizhou Province, School of Basic Medical Sciences/School of Biology and Engineering, Guizhou Medical University, Guiyang 550025, China.
Zuquan HuKey Laboratory of Infectious Immune and Antibody Engineering of Guizhou Province, Engineering Research Center of Cellular Immunotherapy of Guizhou Province, School of Basic Medical Sciences/School of Biology and Engineering, Guizhou Medical University, Guiyang 550025, China.ORCID 0000-0003-4978-4363

Funding

Excellent Young Talents Plan of Guizhou Medical University 2021-101Guizhou Provincial Natural Science Foundation ZK[2022] 349, 2021-5637, ZK2021-029, ZK2022-397, ZK[2022] 381, ZK[2022] 369High-Level Talent Initiation Project of Guizhou Medical University J[2021] 029National Natural Science Foundation of China 32160224Science and Technology Fund Project of Guizhou Provincial Health Commission gzwkj2022-228, gzwkj2021-514Youth Science and Technology Talents Growth Project of Guizhou Ordinary Colleges and Universities KY[2022]220, KY[2022]221, KY[2022]222
6 · The paper itself

Abstract

Isoliquiritigenin (ILQ) has a number of biological activities such as antitumor and anti-inflammatory effects. However, biomedical applications of ILQ are impeded by its poor aqueous solubility. Therefore, in this research, we prepared a novel ILQ-loaded nanoemulsion, i.e., ILQ-NE, which consisted of Labrafil

Indexed as

isoliquiritigeninnanoemulsionphase-inversion composition (PIC)sonication

Identifiers

PMID36004907
PMCPMC9404772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.